Evaluating Efficacy of Pregabalin in Oncology Patients with Neuropathic Pain

Gül, Hakan Levent; Erten, Sebahattin; Gül, Şule Karabulut; Dama, Davut; İnan, Nurten

doi:10.5152/tftrd.2015.78889

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mishra, Bhatnagar, Goyal, Rana, and Upadhya (2012) had made a comparative study to show the efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain, and showed that pregabalin is more efficient in relieving neuropathic cancer pain and neuropathic symptoms as compared to other antineuropathic drugs. Gul, Erten, Gul, Dama, and Aksoy (2016) had evaluated the efficacy of pregabalin in oncology patients with neuropathic pain and reported that pregabalin was found to be highly effective both in short-term and mid-term in oncology patients.…”

Section: Mechanism Of Neuropathic Pain In Patients Withmentioning

confidence: 99%

Duloxetine and pregabalin in neuropathic pain of lung cancer patients

2020

View full text Add to dashboard Cite

Introduction Neuropathic pain occurs in 1% of the population and is difficult to manage. This chronic pain causes psychological distress and impacts patient's quality of life, especially in cancer patients. The aim of this study was to show and compare the efficacy of pregabalin and duloxetine, which are reported in the group of first‐line treatment at European Federation of Neurological Societies (EFNS) guidelines on the pharmacological treatment of neuropathic pain (2010 revision) in lung cancer patients by using visual analogue scale (VAS) and Leeds Assessment of Neuropathic Symptoms and Sign (LANSS). Patients and Methods A prospective, randomized, open label, 3 month of study was conducted. A total of 44 patients that were diagnosed with neuropathic pain (14 women and 30 men) were included in the study. Patient's LANSS and VAS values were recorded before treatment. Then, 22 patients undergo pregabalin and 22 patients undergo duloxetine therapy. But due to side effects (dizziness, constipation), two patients had stopped to use pregabalin. Their LANSS and VAS values were recorded after 1 and 3 months of therapy. Results When we compare LANSS and VAS scores before treatment, after 1 and 3 months of treatment with pregabalin and duloxetine, a significant decrease was observed in both groups at the 1 and 3 months (p < .01). Duloxetine is superior to pregabalin in reducing the LANSS scores when we compare two groups. Conclusions Both duloxetine and pregabalin are effective in the treatment of neuropathic pain of lung cancer patients. And as far as we know, this is the first study comparing the efficacy of duloxetine and pregabalin in the neuropathic pain of lung cancer patients.

show abstract

Section: Mechanism Of Neuropathic Pain In Patients Withmentioning

confidence: 99%

Duloxetine and pregabalin in neuropathic pain of lung cancer patients

2020

View full text Add to dashboard Cite

show abstract

Neuropathic Pain in Cancer: What Are the Current Guidelines?

Mulvey,

Paley,

Schuberth

et al. 2024

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion StatementNeuropathic cancer pain is experienced by 30–40% of patients with cancer. It significantly reduces quality of life and overall wellbeing for patients living with and beyond cancer. The underlying mechanisms of neuropathic pain in patients with cancer are complex and involve direct tumour involvement, nerve compression or infiltration, chemotherapy and/or radiotherapy-induced nerve damage, or post-surgical complications. It is crucial for healthcare professionals to assess and manage neuropathic cancer pain effectively. There is increasing recognition that standardisation of neuropathic pain assessment leads to tailored management and improved patient outcomes. Pain management strategies, including medication, interventional analgesia, physical and complementary therapy, can help alleviate neuropathic pain and improve the patient's comfort and quality of life.

show abstract

Evaluating Efficacy of Pregabalin in Oncology Patients with Neuropathic Pain

Cited by 2 publications

References 0 publications

Duloxetine and pregabalin in neuropathic pain of lung cancer patients

Duloxetine and pregabalin in neuropathic pain of lung cancer patients

Neuropathic Pain in Cancer: What Are the Current Guidelines?

Contact Info

Product

Resources

About